Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Tenet Healthcare ($THC) announced inking a new deal with Humana. The deal allows for all of Tenet's hospitals and hospital-affiliated outpatient centers and employed physicians will be phased back into Humana's network between June and October. The agreement has multiyear tenure. Tenet also announced signing another deal with HCA Holdings ($HCA) which involves sale of its acute care hospitals and related operations in Houston. The company expects to net nearly $725 million from the deal, which is expected to be closed in third quarter of the year.
Tenet stock gained over 12 percent in its pre-market session, trimming its 12 months losses to 51 percent.

Tonix Pharma ($TNXP) stock shot up as the company receiving a new patent from the US Patent and Trademark Office. The patent is named “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride”. It claims the composition and manufacture of a unique formulation that characterizes its PTSD treatment TNX-102 SL. The patent is likely to offer Tonix the U.S. market exclusivity until 2034. TNX-102 SL is an investigational new drug and has not been approved for any indication.
Tonix Pharma stock gained over 6 percent in its pre-market session. The stock has lost 82 percent of its value in the past 12 months.

 
Merck ($MRK) raised its full year guidance. The company now expects to report its annual revenue in the range of $39.1 billion and $40.3 billion, up from previous range of $38.6 billion and $3.87 billion. It expects its Earnings per Share for the entire year to be in the range of $3.67 to $3.87, in comparison to previous estimated range of $3.72 and $3.87.

Sunesis Pharmaceuticals ($SNSS) announced that it has decided to withdraw its European market application for vosaroxin as a treatment for relapsed/refractory acute myeloid leukemia. The company said that its interaction with the European Medicine Agency indicated that the regulator likely would formally adopt a negative opinion in the evaluation of its application.

BioDelivery Sciences ($BDSI) announced that the FDA has broadened the indication for its opioid dependency treatment BUNAVAIL. Now, the drug indication includes induction, or the initial process undertaken when a patient is transitioned from the abused opioid responsible for their addiction to the dose of BUNAVAIL which is intended to provide relief from cravings and withdrawal.

Eli Lilly ($LLY) reported that it has received additional civil investigation demands from attorney generals of Washington state and New Mexico related to the pricing of its insulin products. The company said that the  Washington AG's office demand is related to insulin prices as well as "our relationships with pharmacy benefit managers.

 

Ampio Pharmaceuticals ($AMPE) announced the start of its single injection study of  Ampion drug candidate in patients with severe pain and loss of function associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee. The company said that it plans to advance necessary BLA activities combined with the clinical trial to expedite the path to potential FDA approval.

 

Shire Plc ($SHPG) announced that it has earned $1.23 in net income per share for the first quarter of the year.  Earnings, adjusted for one-time gains and costs, came to $3.63 per share. The company’s revenue for the period stood at $3.57 billion. The company expects full-year earnings in the range of $14.60 to $15.20 per share, with revenue in the range of $14.5 billion to $14.8 billion.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Credit Suisse Group AG
Reiterates
Cardinal Health (CAH)
Buy
$81.00
Low
Hilliard Lyons
Downgrades
Cerner (CERN)
Buy -> Neutral

N/A
Jefferies Group LLC
Reiterates
Quest Diagnostics (DGX)
Neutral -> Hold

Low
Wedbush
Reiterates
Global Blood Therapeutics (GBT)
Outperform
$73.00
Low
Royal Bank of Canada
Raises Target
Integra Lifesciences Holdings Corp (IART)
Sector Perform -> Sector Perform
$46.00 -> $48.00
Low
Ladenburg Thalmann Financial Services
Downgrades
Intra-Cellular Therapies (ITCI)
Buy -> Neutral

Low
Leerink Swann
Downgrades
Intra-Cellular Therapies (ITCI)
Outperform -> Market Perform
$29.00 -> $10.00
Low
Wedbush
Reiterates
Miragen Therapeutics (MGEN)
Outperform
$19.00
Low
Deutsche Bank AG
Reiterates
Qiagen NV (QGEN)
Buy

Low

Gainers (% price change) Last Trade Change Mkt Cap
BioCryst Pharmaceuticals BCRX 6.83 +0.49 (7.73%) 542.99M
The Ensign Group, Inc. ENSG 19.17 +1.22 (6.80%) 919.09M
RTI Surgical Inc RTIX 4.30 +0.25 (6.17%) 253.04M
Cutera, Inc. CUTR 20.50 +0.95 (4.86%) 279.97M
Concord Medical Services CCM 4.60 +0.21 (4.78%) 201.80M
Losers (% price change)
Anthera Pharmaceuticals ANTH 2.36 -0.28 (-10.61%) 172.80M
Cytokinetics, Inc. CYTK 15.40 -1.00 (-6.10%) 642.41M
Infinity Pharmaceuticals INFI 2.02 -0.13 (-6.05%) 104.29M
Accuray Incorporated ARAY 4.38 -0.18 (-3.85%) 358.73M
BioTime, Inc. BTX 3.27 -0.13 (-3.82%) 358.28M
Most Actives (dollar volume)
Pfizer Inc. PFE 33.78 -0.14 (-0.41%) 201.52B
Merck & Co., Inc. MRK 62.38 +0.05 (0.08%) 170.33B
Johnson & Johnson JNJ 123.34 -0.13 (-0.11%) 333.63B
C R Bard Inc BCR 306.92 -0.56 (-0.18%) 22.36B
Regeneron Pharmaceuticals REGN 396.17 +7.68 (1.98%) 44.62B